Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: sstematic review and network meta-analysis including different study designs
Veroniki AA, Antony J, Straus SE, Ashoor HM, Finkelstein Y, Khan PA, Ghassemi M, Blondal E, Ivory J, Hutton B, Gough K, Hemmelgarn BR, Lillie E, Vafaei A, Tricco AC. Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. PLoS One. 2018 Jun 18;13(6):e0198447. doi: 10.1371/journal.pone.0198447.
Commissioner: Health Canada
Funder: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Our results can be used by patients and physicians to tailor administration of these agents
- In comparison with children not exposed to antiretroviral therapy, children exposed to antiretroviral therapy drugs do not face an increased risk of congenital malformations
- However, some antiretroviral therapy agents pose an increased risk of adverse birth events. For instance: zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight
- Some antiretroviral therapy drugs, in particular zidovudine, were effective in reducing mother-to-child transmission of Human Immunodeficiency virus (HIV)
Almetrics:
[/sidebar-content]Category : KS Projects
Date : 07 Jan 2020